
Opinion|Videos|August 13, 2026
Second-Line NCCN Options and Approach to Progression
Author(s)Sandip Patel, MD, Chul Kim, MD
The segment introduces second-line sequencing, reviewing NCCN preferred options after frontline therapy.
Advertisement
Episodes in this series
The segment introduces second-line sequencing, reviewing NCCN preferred options after frontline therapy.This segment reviews a FLAURA2 exploratory analysis on chemotherapy rechallenge and outlines a practical approach to progression. The discussion then addresses how the chemotherapy-free interval influences the decision to rechallenge with platinum/pemetrexed versus moving to an amivantamab-based regimen or datopotamab deruxtecan. The segment closes by differentiating between datopotamab deruxtecan and amivantamab plus chemotherapy in the subsequent-line setting, citing TROPION-Lung01 and TROPION-Lung05 data.
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

